Dr. Chun Wang is a leading expert in hematopoietic stem cell transplantation (HSCT) and infection management in hematologic disorders in China. With more than three decades of extensive clinical and research experience, he has dedicated his career to the diagnosis and treatment of malignant hematologic diseases, particularly adult and elderly HSCT. He previously served as Director of the Department of Hematology at Shanghai General Hospital and completed postdoctoral training at the Bone Marrow Transplant Center of the Ontario Cancer Institute in Canada, where he gained systematic expertise in transplantation medicine and infection control. Over the years, Dr. Wang has performed several thousand HSCT procedures, establishing a strong clinical foundation across transplant modality selection, management of complex and high-risk cases, post-transplant infectious complications, and immune reconstitution.
Dr. Wang led the compilation of China’s first Clinical Application Guidelines for Antibacterial Agents in Patients with Neutropenia and Fever (2012 edition), which marked an important milestone toward evidence-based and standardized infection management in hematology nationwide. As a major driving force in China’s transplantation field, he and his team were the first in the country to perform allogeneic HSCT for the treatment of myelofibrosis, achieving breakthrough success. He has also accumulated extensive experience in transplantation strategies for elderly patients, refractory or relapsed lymphoma, multiple myeloma, and severe aplastic anemia. The team’s key technologies for “Allogeneic HSCT in Salvage Treatment of Refractory Malignant Hematologic Diseases” earned the Second Prize of the Scientific and Technological Progress Award from both the Ministry of Education and the Chinese Medical Association.
Dr. Wang has published widely in internationally recognized journals such as Clinical Infectious Diseases, Journal of Clinical Oncology, and Blood Cancer Journal, and is acknowledged domestically and internationally as an authority in HSCT and infection management.













